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Objective: Surfactant proteins A and D are important molecules involved in lung
allograft innate immunity. Genetic polymorphisms of surfactant proteins A and D
are associated with various lung diseases. In this study, surfactant protein A and D
expression responses were investigated during pharmacogenetics upon
methylprednisolone treatment as observed during lung transplantation.
Methods: A human cell line (NCI-H441) and precision-cut lung slices from 16
human donors were incubated with methylprednisolone, and surfactant protein
A1, surfactant protein A2, and surfactant protein D messenger RNA and
surfactant protein A protein expression were assayed. Surfactant protein A1,
A2, and D polymorphisms and surfactant protein A gene and protein expressions
were determined.
Results: In NCI-H441 cells, methylprednisolone treatment at 105M and 106M
reduced surfactant protein A1 and surfactant protein A2 messenger RNA and
surfactant protein A protein expression (P<.05). A pharmacogenetic relationship
was observed in human donor precision-cut lung slices between the surfactant
protein A2 (1Ax) variants: Surfactant protein A1, A2, and D messenger
RNA expression were greater for 1A0 versus 1A1 (P< .05); surfactant protein
A1/surfactant protein A2 genotype 6A26A2/1A01A0 (n ¼ 5) showed greater
surfactant protein A1, A2, and D messenger RNA expression and surfactant
protein A protein expression compared with the other surfactant protein
A1/surfactant protein A2 genotypes (n ¼ 11) (P<.05).
Conclusions: The surfactant protein A genotype and methylprednisolone stimuli
influence donor lung surfactant protein A and D expression. Lungs carrying the
surfactant protein A2 variant 1A0 have a greater expression of surfactant protein
A when treated with methylprednisolone. Surfactant protein A polymorphisms
could be used to personalize immunosuppressive regimens. (J Thorac Cardiovasc
Surg 2019;157:2109-17)From the aDivision of Thoracic Surgery, Columbia University Medical Center, New
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6A26A2-1A01A0 Other 6A26A2-1A01A0 Other
SP-A1/SP-A2 genotype
Methylprednisolone influences SP-A mRNA and
protein expression according to SP-A genotypes.Central Message
Our study, although acquired from a small
cohort of human donor lungs, for the first
time showed that the SP-A genotype and
methylprednisolone stimuli influence donor
lung SP-A and SP-D expression.Perspective
This study, as the first reference for future
pharmacogenetic studies in lung transplanta-
tion, may provide the basis for novel
immunosuppressive regimens tailored accord-
ing to the genetic background of the donor
lung. Further studies are required on donor
lungs for the purposes of identifying different
genotypes to predict the response of these
genotypes to methylprednisolone treatment.See Commentaries on pages 2118 and
2119.To date, lung transplantation is a good option to counter
end-stage lung disease. Long-term outcome is still
challenged by multiple dangerous events (ie, infections,
rejection, and gastroesophageal reflux micro-aspiration)
that contribute to a suboptimal survival.1-3 Pulmonary
surfactant provides the lung with one of its innate defense
mechanisms consisting of a mixture of phospholipids and
surfactant protein (SP)-A, SP-D, SP-B, and SP-C.4-6 SP-A
and SP-D (collectins serving as opsonins) have also been
shown to orchestrate lung immunity by regulating cytokine
production in macrophages and neutrophils while also




mRNA ¼ messenger RNA
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proliferation.7,8 Determining the regulation of these proteins
in lung transplantation is important when selecting the
optimal treatment strategy.
Human SP-A and SP-D genes reside in the same
chromosome (10q22.2-23.1). SP-A is encoded by 2 genes,
SP-A1 and SP-A2, with several polymorphisms within the
coding region.9,10 Three coding single nucleotide
polymorphisms (SNPs) of the SP-D gene have been
described for amino acid residue 11 (Met11Thr), 160
(Ala160Thr), and 270 (Ser270Thr), the latter being
infrequent.11,12 Gene polymorphisms of the SP-A1,
SP-A2, and SP-D proteins may be responsible for
quantitative or qualitative differences that may include
reduced levels of protein production and variations in
protein functionality.9,10 SP-A and SP-D gene variants are
associated with respiratory distress syndrome, idiopathic
pulmonary fibrosis, emphysema, and other lung dis-
eases.11-19
Expression of SP-A and SP-D is regulated by cAMP,
thyroid transcription factor-1, and glucocorticoids.20-22
SP-A genes and variants have been suggested to display a
variety of responses to glucocorticoids.20-22 This is of
interest in lung transplantation given that donor lungs are
treated with elevated doses of methylprednisolone before
organ retrieval and that the recipient standard
immunosuppressive regimen also includes relatively high
doses of prednisone.23 Lung allografts with low levels of
SP-A messenger RNA (mRNA) expression just before
implantation are associated with reduced survival.24
Furthermore, donor lung SP-A2 polymorphisms are associ-
ated with greater incidence of pneumonia and reduced
survival.25 In contrast, SP-D variants were associated with
development of chronic lung allograft dysfunction.26
Given these observations, we hypothesized a pharmacoge-
netic relationship of SP-A and SP-D variants and methyl-
prednisolone. This would be relevant in the context of lung
transplantation because lung allografts are exposed to high
levels of steroids both before procurement and during the first
post-transplant period. By using donor precision-cut lung
slices (PCLS) and cell cultures in vitro, we studied the effect
ofmethylprednisolone on SP-A and SP-D expression accord-
ing to the different genotypes as determined by the SP-A1
and SP-A2 haplotypes and the 2most frequent SP-D variants,
residue 11 (Met11Thr) and residue 160 (Ala160Thr).2110 The Journal of Thoracic and Cardiovascular SurMATERIALS AND METHODS
Cell Cultures
NCI-H441 cells (American Type Culture Collection, Manassas, Va)
were cultured in Roswell Park Memorial Institute 1640 medium
supplemented with 10% fetal bovine serum and 1% penicillin/
streptomycin (Invitrogen, Carlsbad, Calif). Cells were grown in T-25 flasks
at 37C in 5% CO2 humidified atmosphere. Cells during passages 10 to 15
were plated at approximately 80% confluence and cultured for 24 hours
using incremental doses (105, 6, 7, 8, 9 M) of methylprednisolone
(Sigma, St Louis, Mo). Control cells received the vehicle 0.01% (v/v)
dimethyl sulfoxide.
Precision-Cut Lung Slice Cultures
Human PCLS were obtained in accordance with Columbia University
Medical Center research ethics review board. The donor’s proxy and
transplant recipients consented for the use of lungs for research in adherence
to the principles set forth in theHelsinki Declaration. Donor clinical datawere
not available. Lung samples from 16 donors were infused with 3%
low-melting agarose solution (Sigma Aldrich, Munich, Germany) and cooled
on ice. PCLS were obtained 300 mm thick and 8 mm in diameter (Krumdieck
tissue slicer, Alabama Research and Development, Munford, AL). PCLS
were cultured in Dulbecco’s Modified Eagle’s medium/nutrient mixture
F-12 Ham with L-glutamine and 15 mmol/L HEPES (Sigma Aldrich,
Munich, Germany) with 10% fetal bovine serum, 100 U/mL penicillin,
and 100 mg/mL streptomycin (Invitrogen, Carlsbad, Calif). PCLS were
cultured for 48 hours at 37C in a humidified atmosphere of 5% CO2. After
24 hours of culture, PCLS were supplemented with methylprednisolone
(0 and 105 M) for 24 hours. Experiments were performed in duplicate or
triplicate pending on tissue availability. After stimulations, PCLS were
snap-frozen in liquid nitrogen and stored at 80C before analysis.
Reverse Transcription-Polymerase Chain Reaction
RNAwas isolated with RNeasy kits (QIAGEN, Valencia, Calif). RNA
was reverse transcribed to cDNA using the High-Capacity cDNA Kit
(Applied Biosystems, Carlsbad, Calif). Quantitative polymerase chain
reaction was performed using the TaqMan Gene Expression Assays in an
ABI 7300H polymerase chain reaction system (Applied Biosystems). Taq-
Man primers for SP-A1 (HS01921510_S1), SP-A2 (HS00359837_M1),
SP-D (HS01108490_M1), glyceraldehyde-3-phosphate dehydrogenase
(GADPH) (HS999999905M1), and 18S rRNA (Hs99999901_s1) were
used. GADPH and 18S rRNA served as endogenes for cells and PCLS,
respectively. Relative quantification was calculated.
Protein Quantification
Cells were homogenized in RIPA lysis buffer (Thermo Fisher,
Rockford, Ill). The homogenate was centrifuged for 10 minutes at
13,000g. Proteins were quantified using the BioRad assay (BioRad,
Hercules, Calif). Immunoblots were undertaken with 10 mg of human
SP-A antibody (Santa Cruz Biotechnology, Santa Cruz, Calif) at
0.2 mg/mL. Blots were detected by anti-goat horseradish
peroxidase–conjugated secondary antibody, followed by enhanced
horseradish peroxidase chemiluminescence (Thermo Fisher) and
autoradiography. Bands were semiquantified using Quantity One Image
software (Kodak MI 4.0). Cell protein levels were normalized to GADPH
or cyclophilin A (Abcam, Cambridge, Mass).
Surfactant Protein Genotype
Donor lung DNAwas analyzed in a blinded fashion. SP-A1 (6Ax6Ax),
SP-A2 (1Ax1Ax) variant and SP-D gene variants Met11Thr, Ala160Thr were
assessed using a pyrosequencing protocol as previously described.10,19,27
Pyrograms were scored by pattern-recognition software comparing the
predicted single nucleotide polymorphism pattern (histogram) with the
observed pattern (pyrogram) (Pyrosequencing AB, Uppsala, Sweden).gery c May 2019
Aramini et al Thoracic: Lung Transplant: Basic ScienceStatistical Analysis
RNA and protein expression are reported as median (25th-75th percen-
tile range). Box plot graphs represent themedian at the 25th-75th percentile
range and bars at the 10th and 90th percentile. We used Kruskal–Wallis
tests to compare continuous variables across categories. When the
Kruskal–Wallis test was P less than .05, we used the Mann–Whitney test
to compare continuous variables between categories to preserve an overall
alpha of 0.05. Statistical analysis was performed using SAS 9.2 software





Methylprednisolone Treatment of Human Lung Cells
The NCI-H441 cells were used because they express
SP-A28 and were found to have an SP-A1/SP A2 genotype
6A46A4/1A51A5.29 SP-A1 and SP-A2 m RNA expression
in this cell line was assayed after treatment with
methylprednisolone at incremental doses. The data were
expressed as relative quantification. SP-A1 mRNA
expression was as follows: for methylprednisolone
concentration of 105 M, median 0.38 (25th-75th percentile
range, 0.25-0.5); for 106 M, 0.416 (0.4-1.2); for 107 M,
1.3 (0.3-2.1); for 108 M, 1.2 (0.9-2.3); for 109 M,
1.2 (0.9-1.6) (Kruskal–Wallis P ¼ .0087; Mann–Whitney
test for 105 M vs 108 M P ¼ .0043 and vs
109 M P¼ .0043) (Figure 1, A). SP-A2 mRNA expression
was as follows: for methylprednisolone, concentration
105 M, median 0.6 (0.45-0.6); for 106 M, 0.84
(0.5-3.6); for 107 M, 1.68 (0.9-3.4); for 108 M, 1.26
(0.85-5); for 109 M, 1.2 (1.0-2.8) (Kruskal–Wallis
P ¼ .0506; Mann–Whitney test for 105 M vs
108 M P ¼ .0152 and vs 109 M P ¼ .026) (Figure 1,
































FIGURE 1. A, Relative quantification of SP-A1 and SP-A2 mRNA expression
tests for 105 M versus 108 M showed *P ¼ .022 and for 105 M versus 109
mRNA expression for cells without treatment (control) median was 0.75 (0.6-1.3
revealed that methylprednisolone at high concentrations (105 M to 106 M) had
groups. SP-A densitometry was normalized to GADPH and relative to control de
*Denotes P¼ .0022 for 105 M and P¼ .0004 for 106 M compared with vehic
(control) median: 0.9 (0.7-1.3). SP, Surfactant protein.
The Journal of Thoracic and Carmethylprednisolone 105 M, median 0 (0-0.02); for
106 M, 0.02 (0-0.3); for 107 M, 0.3 (0.01-1.82); for
108 M, 0.52 (0.14-1.24); for 109 M, 0.48 (0.03-1.4)
(Kruskal–Wallis P ¼ .0051; Mann–Whitney test for
10⁻5 M vs 107 M P ¼ .026, 108 M P ¼ .0022, and
109 M P ¼ .002) (Figure 1, B).
SP-A variants affect methylprednisolone responses in
human PCLS. SP-A1 and the SP-A2 variant frequency
(Table 1) and genotypes (Table 2) were examined
for each of the 16 human donors. In 5 donor lungs, the
SP-A1/SP-A2 genotype was 6A26A2/1A01A0. The donor
PCLS were grouped for comparisons according to the
presence or absence of the 2 most frequent variants
for SP-A1 6A2 (n ¼ 7) and 6A3 (n ¼ 4), for SP-A2
variants 1A0 (n ¼ 8) and 1A1 (n ¼ 4) (lungs with SP-A1
genotype 6A2-6A3 and SP-A2 genotype 1A0-1A1
were excluded from the groups), and according to
SP-A1/SP-A2 genotype, 6A26A2/1A01A0 (n ¼ 5) to be
compared with the remaining 11 lungs with a
heterogeneous variety of genotypes grouped together
and identified as ‘‘other.’’
Methylprednisolone treatment of the PCLS with high
(105 M) or low (109 M) doses showed no difference in
the SP-A1 and SP-A2 mRNA expression in all groups
(Table 3). Subsequent data comparisons between groups
were performed irrespective of the methylprednisolone
dose.
After methylprednisolone treatment, donor PCLS
grouped for SP-A1 variants showed that SP-A1 mRNA
expression was for variant 6A2 median 2.9 (2.4-3.7) and



































. For SP-A1, Kruskal–Wallis test showed P<.009; Mann–Whitney exact
M P ¼ .043. For SP-A2, Kruskal–Wallis test showed P ¼ .054. The SP-A1
); the SP-A2 for control median was 0.98 (0.8-1.2). B,Western blot analysis
significantly decreased SP-A protein expression levels compared between
nsitometry values were determined. Kruskal–Wallis test showed P¼ .0051.
le treated cells by Mann–Whitney tests for protein. Cells without treatment
diovascular Surgery c Volume 157, Number 5 2111
TABLE 1. Surfactant protein A1 (6Ax) and A2 (1Ax) allele frequency





6A2 16 (50%) 1A0 14 (44%)
6A3 11 (34%) 1A1 6 (20%)
6A 2 (6%) 1A 4 (12%)











for 6A2 median 2 (0.5-5.4) and for 6A3 median
0.5 (0.07-2.2). No significant association was noted for
the protein expression.
After methylprednisolone treatment, donor PCLS
grouped according to SP-A2 variants showed
(Figure 2, A) that SP-A1 mRNA expression was for group
1A0 median 2.33 (25th-75th percentile range 1.5-3.9) and
for group 1A1 median 0.9 (0.5-1.6) (P ¼ .1). The SP-A2
mRNA expression was for group 1A0 median 2.2
(1.8-3.6) and for group 1A1 median 0.74 (0.5-0.9)
(P ¼ .017). The SP-A protein expression was also lower
in PCLS from SP-A2 variant 1A1 donors (median ¼ 0.45,
25th-75th percentile range ¼ 0.11-2.02) compared with
1A0 variant (median ¼ 1.462, 25th-75th percentile
range ¼ 0.43-3.41), although this was not statistically
significant (Mann–Whitney P ¼ .23) (Figure 2, B). After
treatment with methylprednisolone, donor PCLS grouped
according to the SP-A1/SP-A2 genotype (Table 2) showedTABLE 2. Combinations of the observed polymorphic surfactant protein
SP-A2 genotype 6A6A2 6A6A4 6A26A2 6
1A1A0 1 0 0
1A1A1 0 0 0
1A1A2 0 1 0
1A1A3 0 0 0
1A01A0 0 0 5
1A01A1 0 0 0
1A01A2 0 0 0
1A01A5 0 0 0
1A11A1 0 0 0
1A11A2 0 0 0
1A11A8 0 0 0
1A31A15 0 0 0
Total 1 1 5
SP, Surfactant protein.
2112 The Journal of Thoracic and Cardiovascular Sur(Figure 3, A) that SP-A1 mRNA expression was as follows:
for group 6A26A2/1A01A0 median 3.9 (2.4-4.1) and for
group ‘‘other’’ 0.8 (0.6-3.1.8) (P ¼ .004). The SP-A2
mRNA expression was for 6A26A2/1A01A0 median
2.1 (1.9-2.7) and for group ‘‘other’’ 0.9 (0.6-1.7)
(P ¼ .047). Similar to findings for SP-A2 variants, after
methylprednisolone treatment, PCLS from donor lung
with SP-A1/SP-A2 genotypes showed that SP-A protein
expression was higher compared with the ‘‘other’’ group
(Figure 3, B). In particular, SP-A protein expression was
for genotype 6A26A2/1A01A0 median 1.5 (1.2-8.7), and
for the ‘‘other’’ genotypes was median 0.3 (0.2-1.5)
(Mann–Whitney test P ¼ .042).Surfactant Protein D Variants and
Methylprednisolone Responses in Human
Precision-Cut Lung Slices
The polymorphisms for aa11 (Met11Thr) and aa160
(Ala160Thr) of the donor lungs are shown in Table 4. After
methylprednisolone treatment, SP-D mRNA expression in
the PCLS cultures showed no significant association with
the aa11 and the aa160 variants (Figure 4). SP-D mRNA
expression after treatment of PCLS with methylpredniso-
lone was significantly associated with the SP-A
polymorphic groups. PCLS were grouped according to the
SP-A2 variants showing (Figure 4) SP-D mRNA expression
for group 1A0 median 2.1 (0.8-6.2) and for group 1A1
median 0.7 (0.4-1.3) (Mann–Whitney test P ¼ .04). No
association was observed for the SP-A1 variant groups.
SP-D mRNA expression in PCLS was grouped according
to donor SP-A genotype (Figure 4): for genotype
6A26A2/1A01A0 median 2.3 (2.1-7.9) and for the ‘‘other’’
median 0.6 (0.4-1.3) (Mann–Whitney test P ¼ .006).A1 (6Ax6Ax) and A2 (1Ax1Ax) genotypes in human donor lungs
SP-A1 genotype
A26A3 6A26A4 6A36A3 6A36A4 Total
0 0 0 0 1
0 0 1 0 1
0 0 0 0 1
1 0 0 0 1
0 0 0 0 5
0 0 1 0 1
1 0 0 0 1
0 1 0 0 1
0 0 1 0 1
0 0 0 1 1
1 0 0 0 1
1 0 0 0 1
4 1 3 1 16
gery c May 2019
TABLE 3. Surfactant protein A1 and A2 mRNA expression and methylprednisolone doses
Methylprednisolone
SP-A1 mRNA SP-A2 mRNA
109 M 105 M P 109 M 105 M P
All lungs (n ¼ 16) 0.97 (0.6-2.2) 1 (0.7-2.5) .6 1.4 (0.8-2) 1.3 (0.7-2.9) .7
SP-A1 variant groups
6A2 (n ¼ 11) 2.5 (0.7-3.2) 2.3 (0.6-3.5) .9 1.8 (0.3-2.8) 1.3 (0.5-4.6) .9
6A3 (n ¼ 4) 2.5 (0.4-5) 1 (0.2-2.5) .4 0.5 (0.2-1.6) 1 (0.4-2.2) .6
SP-A2 variant groups
1A0 (n ¼ 8) 1.7 (0.9-3.3) 2.2 (1-2.9) .7 1.6 (1.4-2.9) 2.9 (1.1-4.6) .4
1A1 (n ¼ 4) 0.7 (0.3-1.1) 1 (0.66-2.2) .4 0.5 (0.3-1) 0.7 (0.5-1) .6
Genotype groups
6A26A2-1A01A0 (n ¼ 5) 2.6 (2-5.9) 2.3 (1.9-3.8) .7 1.6 (1.5-3.2) 2.6 (1.3-3.5) .7
Other (n ¼ 11) 0.8 (0.61) 0.9 (0.5-1.7) .4 1.1 (0.6-1.9) 1.1 (0.6-1.9) .9
mRNA, Messenger RNA; SP, surfactant protein.






This study is the first attempt to investigate the
pharmacogenetic relationship between SP-A and SP-D
polymorphisms and the impact of methylprednisolone on
SP-A and SP-D expression in human lung parenchyma,
particularly within lung transplantation. Our data further
support the notion that SP-A polymorphisms provide
regulation of the SP-A expression in the lung. We
documented in a human pulmonary cell line, and as shown
in the Graphical Abstract, in human donor PCLS the
relationship between SP-A gene polymorphisms and theA




























FIGURE 2. A, Quantitative reverse transcription-polymerase chain reaction ass
24 hours of PCLS with methylprednisolone. Relative quantification was expre
variants: group 1A0 and group 1A1 (donor lung with genotype 1A01A1 w
**P ¼ .02. In PCLS without treatment (control) the SP-A1 mRNA expression
was 1.18 (0.3-1.5). The SP-A2 expression in control PCLS was for group 1A0
B, Western blot analysis revealed that SP-A protein levels are reduced in PCLS
109M) compared with 1A0 SP-A2 variant treated with methylprednisolone (
A, relative densitometry values were determined, and representative blots are
gene expression and for protein changes, with * denoting a P value ¼ .23. Th
1A0 median 0.68 (0.2-2.0) and for group 1A1 median 0.96 (0.05-2). SP, Surfac
The Journal of Thoracic and Carinfluence of methylprednisolone on SP-A expression. The
findings revealed that the SP-A expression after treatment
with methylprednisolone differed according to the SP-A2
polymorphism. Human lungs with SP-A2 variant 1A0
(Figures 2 and 3) had a significantly greater SP-A
expression when treated with methylprednisolone. We
also observed that the SP-A2 pharmacogenetics also
associated with SP-D expression. This pilot study
stimulates further research investigating immunosuppres-
sive regimens also tailored according to the genetic


































essment of the mRNA expression for SP-A1 and SP-A2 after incubation for
ssed according to the presence or absence of the 2 most frequent SP-A2
as excluded from the groups). Mann–Whitney exact test showed for
was for group 1A0 median was 0.78 (0.6-1.7) and for group 1A1 median
median was 0.45 (0.4-2.3) and for group 1A1 median was 1.05 (0.2-1.8).
with a 1A1 SP-A2 variant treated with methylprednisolone (105 M and
105 M and 109 M). SP-A densitometry was normalized to cyclophilin
shown. Mann–Whitney test was used to determine significant changes for
e SP-A protein levels in PCLS without treatment (control) was for group
tant protein.






























































6A26A2-1A01A0 Other 6A26A2-1A01A0 Other
SP-A1/SP-A2 genotype
FIGURE 3. A, Quantitative reverse transcription-polymerase chain reaction assessment of the mRNA expression for SP-A1 and SP-A2 after incubation for
24 hours of PCLSwith methylprednisolone. Relative quantification was expressed according to the genotype 6A26A2/1A01A0 and the remaining 11 grouped
as ‘‘other.’’ Mann–Whitney exact test showed for * P ¼ .002 and for **P ¼ .0002. In PCLS without treatment (control), the SP-A1 mRNA expression for
group 6A26A2/1A01A0 was median 0.86 (0.4-1.7) and in ‘‘other’’ median was 0.94 (0.4-1.8); the control SP-A2 mRNA for group 6A26A2/1A01A0 median
was 0.52 (0.4-1.9) and in ‘‘other’’ median was 0.64 (0.3-1.6). B, Western blot analysis revealed that SP-A protein levels are greater in PCLS with
6A26A2/1A01A0 genotype treated with methylprednisolone compared with the remaining 11 grouped as ‘‘other’’ treated with methylprednisolone. SP-A
densitometry was normalized to cyclophilin A, relative densitometry values were determined, and representative blots are shown. The Mann–Whitney
test was used to determine significant changes, with * denoting a P¼ .042. The SP-A protein levels in control PCLS for group 6A26A2/1A01A0 was median
0.37 (0.29-2.0) and for the ‘‘other’’ group control median 0.5 (0.18-1.2). SP, Surfactant protein.





We initially tested human lung adenocarcinoma
NCI-H441 cells. These cells were chosen because they
are the only cells that express SP-A in a consistent
manner.28-31 Of note, the NCI-H441 human cell line
expresses an uncommon SP-A1/SP-A2 genotype
(6A46A4/1A51A5).32 NCI-H441 cells were treated with
methylprednisolone at a 10-fold incremental dose from
109 M to 105 M. Methylprednisolone at high
concentrations significantly reduced the mRNA and protein
expression of SP-A compared with lower doses. These
observations confirm what was previously reported
using dexamethasone in the same cell line.28,29
Methylprednisolone and dexamethasone, although both
are glucocorticoids, have different clinical applications
and dexamethasone rarely is used in clinical lung
transplantation because it is associated with worse clinicalTABLE 4. Observed frequency for surfactant protein D variants
residue 11 (Met11Thr) and residue 160 (Ala160Thr) in human donor
lungs
SP-D variant
Ala160Ala Ala160Thr Thr160Thr Total
Met11Met 3 1 2 6
Met11Thr 6 3 0 9
Thr11Thr 1 0 0 1
Total 10 4 2 16
Values are the number of patients with the specified SP-D variant. SP, Surfactant
protein.
2114 The Journal of Thoracic and Cardiovascular Suroutcomes. A similar investigation was then conducted in a
human donor PCLS culture model. This is a more difficult
model to implement, particularly from a logistic
standpoint given that human donor lungs available for
research are a scarce resource, although it is the most
relevant biological model from which meaningful clinical
conclusions can be drawn. The SP-A1 and SP-A2 variant
frequencies seen in our donor lung study population
(Table 1) reflect that of the larger patient populations
described in the literature.10,13,27 Within the cohort of 16
donor lungs tested, 5 lung grafts (Table 1) had the
SP-A1/SP-A2 genotype 6A26A2/1A01A0, which is
the most common genotype identified in the human
population.10,13,27
When investigating PCLS in human donors and the
pharmacogenetic relationship between methylprednisolone
treatment and the SP-A1 and SP-A2 most frequent variants,
our results indicated that the SP-A1 variants 6A2 and 6A3
had no influence on the response of the SP-A1 and SP-A2
mRNA expression. In contrast, PCLS obtained from lungs
grouped according to the presence of SP-A2 alleles 1A0
or 1A1 showed a different response: SP-A2 variant 1A0
had a greater mRNA and protein expression after
methylprednisolone treatment and seems to be stimulated
by methylprednisolone treatment, although variant 1A1
seems to be inhibited by the steroid (Figure 2, A).
Donor lungs with the SP-A1/SP-A2 genotype
6A26A2/1A01A0 compared with the other donor lungs that






























1A0 1A1 6A26A2-1A01A0 “Other”
SP-A1/SP-A2 genotypeSP-A2 alleles
***
FIGURE 4. SP-A2 variants and genotypes influence SP-D expression
after methylprednisolone treatment. Quantitative polymerase chain
reaction was performed for SP-D mRNA expression after incubation for
24 hours of the PCLS with methylprednisolone. Relative quantification
of the SP-D mRNA is expressed as fold differences of mRNA expression
relative to the untreated control samples in PCLS grouped according to
SP-A2 variants 1A0 and 1A1 and according to the SP-A1/SP-A2 genotype
6A26A2/1A01A0, and the remaining 11 grouped as ‘‘other.’’ Only
methylprednisolone-treated analyses are shown (105 M and 109 M
combined data). Mann–Whitney test *P ¼ .04, **P ¼ .006. The SP-D
mRNA expression in PCLS without treatment (control) was for group
1A0 median 0.6 (0.3-1.9) and for group 1A1 median 1 (0.6-1.3); for group
6A26A2/1A01A0 median 1.1 (0.3-1.56); and for the ‘‘other’’ group median
1 (0.6-1.2). SP, Surfactant protein.





(Table 2) consistently showed a significantly greater SP-A1
and SP-A2 mRNA (Figure 3, A) and SP-A
protein expression after methylprednisolone treatment
(Figure 3, B). Moreover, SP-D expression was also subject
to the SP-A pharmacogenetic interaction with methylpred-
nisolone (Figure 4). In contrast, no pharmacogenetic
relationship was noted with the 2 most frequent SP-D single
nucleotide polymorphisms (aa11 and aa160) that were
investigated. It is not understood how the pharmacogenetic
relationship between methylprednisolone and SP-A2
variants is associated with SP-A 1 and SP-D expression.
SP-A2 was recently shown to regulate microRNA, which
we speculate could in turn regulate the SP-A and SP-D
expression.33
The results derived from the human donor PCLS model
were different from the findings using the human lung
cancer cell model with an SP-A1/SP-A2 genotype
6A46A4/1A51A5. The cell line showed a significant
reduction of SP-A expression when methylprednisolone
was used at high doses (Figure 1), but this was not observed
at low doses. The human cancer cells we have used in this
study express a rare SP-A genotype. Although the results
are from different models (immortalized adenocarcinoma
cells and PCLS cultures), it is possible that some of the
less frequent or rare genotypes encountered in the human
population may eventually show a similar response as
observed in NCI-H441 cells.The Journal of Thoracic and CarGlucocorticoids have been shown to have a biphasic
regulation of the SP-A expression either stimulating or in-
hibiting accumulation in cultured human fetal lungs
depending on the dose and time of exposure.30,31
Moreover, there appears to be a differential regulation of
the SP-A1 and SP-A2 genes.24,25,31,32 Glucocorticoid
treatment in vivo using a preterm sheep model triggered
SP-A expression.34 The concentrations of methylpredniso-
lone used in our experiments mimic those reported in the
literature investigating in vitro the hormonal regulation of
SP-A expression.28-32,34 How they relate to the doses used
in the clinical transplant setting is difficult to extrapolate.
It is not possible to exactly compare the doses used
regularly in clinical treatment administered intravenously
according to patient weight with the concentration of the
drug administered in the culture media in our cell and
PCLS cultures, and not knowing the weight of the cells
and tissues.
Our results in the human PCLS model showed no
influence of the methylprednisolone dose but did show a
definite diverse pattern of SP-A expression according to
the SP-A polymorphic variants. Our results suggest that
lung allografts according to their SP-A genotypes may be
able to provide potentially greater or less active surfactant
innate immune system after lung transplantation, given
the same regimen of steroid treatment. In particular, lungs
with SP-A genotype 6A26A2/1A01A0 showed a signifi-
cantly greater SP-A expression after methylprednisolone
treatment (Figure 3, A and B).
The information generated from our study is of interest
given that the lung-specific innate immunity provided by
surfactant and its proteins plays an important role in the first
line of defense from the various noxious events encountered
in lung transplantation.1-3 SP-A was reduced in a rodent
model of lung transplant ischemia–reperfusion injury, and
endobronchial treatment with SP-A–enriched surfactant
improved lung function.35 Moreover, in humanized
transgenic mice in which each was carrying a different
SP-A variant, differences in lung function were observed
after infection.36 We reported that the donor lung allograft
SP-A and SP-D polymorphism influence the post-
transplant outcomes.24-26 In particular, SP-A2 variant 1A0
has a protective effect toward survival. In humanized
transgenic mice, those carrying SP-A2 variant 1A0 had
greater survival after Klebsiella pneumonia infection.37
Lung transplant recipients of allografts with SP-A2
genotype 1A0-1A0 had significantly greater SP-A mRNA
expression before implantation, which resulted in
improved clinical outcomes.24,25 Of note, donors
before organ procurement are treated with 1 to 2 g of
intravenous methylprednisolone every 12 hours, and lung
transplant recipients are treated with 0.5 mg/kg of
methylprednisolone early post-transplant, which is
slowly tapered over the first year, thereafter reaching adiovascular Surgery c Volume 157, Number 5 2115





maintenance dose of 5 to 10 mg twice per day. Reduced
levels of SP-A and SP-D proteins in the bronchoalveolar
lavage collected at surveillance bronchoscopies in lung
transplant recipients are associated with the development
of lung allograft dysfunction.38
CONCLUSIONS
Our findings, although acquired from a small cohort of
human donor lungs, show for the first time and serve as
proof-of-concept that there is a significant pharmacogenetic
relationship between the SP-A polymorphic genotype and
the methylprednisolone treatment on SP-A expression. Of
note, these findings are donor lung related and not recipient
driven. Further studies are required on donor lungs for the
purpose of identifying different genotypes that are
associated with different patterns of expression from that
observed in the current cohort of human donor lungs or
the human cancer cell line genotype as a response of these
genotypes to methylprednisolone treatment. These findings
will need to be confirmed in vivo. The findings from this and
future pharmacogenetic studies in lung transplantation may
stimulate further research investigating immunosuppressive
regimens tailored according to the genetic background of
the donor lung. These putative future regimens could then
be implemented in the routine management of lung
transplant recipients.
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